MONTREAL, /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...
Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...
Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations -- Program will ...
Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...
Detailed price information for Aytu Biopharma Inc (AYTU-Q) from The Globe and Mail including charting and trades.
Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue ...
Harmony Biosciences Holdings, Inc. today announced strong preliminary, unaudited net product revenue for Q4 and full year ...
Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan. Eisai and Nuvation Bio Enter into Exclusive ...
Objectives Studies to date have under-represented cardiac characteristics of para athletes, despite their unique cardiovascular physiology and risks. This study examined the cardiac electrical and ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...
Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback